Black Woman Makes History by Becoming the First Doctor to Cure Can-cer Using Nanoparticles - Video

Dr. Hadiyah-Nicole Greena multidisciplinary chemist and the second African American woman to graduate from the University of Alabama at Birmingham with a PhD in physics has become the first to effectively cure can-cer utilizing laser-activated nanoparticles. She received a $1.1 million grant to expand her research on malignancy treatment with nanoparticles, according to Black Culture News.

Dr. Green's revolutionary nanoparticle technology, as the founder of the Ora Lee Smith Can-cer Research Foundation, does not require patients to undergo chemotherapy, radiation, or surgery and was found to successfully cure after mice testing within 15 days.

Her passion for finding a better way to combat malignancy led her to obtain a bachelor's degree in physics and optics from Alabama A&M University and later to earn a Master's degree in physics from Birmingham University of Alabama, both of which she received full scholarships. Since graduation, she moved for five years to the Comprehensive Ca-nc er Center, then one year to the Pathology Division.

Dr. Green's involvement in treatment comes from witnessing the loss of her daughter, Ora Lee, who gone from this problem and her brother, General Lee Smith, who was also diagnosed with malignancy and witnessed the negative side effects of conventional chemotherapy treatment, according to Black Culture Today.

Dr. Green's Ora Lee Smith Research Foundation is currently continuing to use laser-activated nanoparticles to fight for it and is focusing on its mission to make treatment accessible, affordable and effective. She's even dedicating time to helping young Black people.

Upon graduation, she took up a role as an assistant professor at the Department of Material Science and Engineering at Tuskegee University. Then she became an associate professor in the Department of Physiology at Morehouse School of Medicine.

Thank you, Dr Hadiyah-Nicole Green, for your dedication to medicine and advancing ca n-cer treatment research.